ArticleInfection2019
Nitroxoline: an option for the treatment of urinary tract infection with multi-resistant uropathogenic bacteria.
Article in Infection, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 12 citations in OpenAlex.
- Repurposing Analysis of Nitroxoline (8-Hydroxy-5-nitroquinoline) as an Antichagasic Compound.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Combinatory Effect of Nitroxoline and Gentamicin in the Control of Uropathogenic Enterococci Infections.Antibiotics (Basel, Switzerland) · 2024Article
- Summary of guidelines from the Polish Urological Association, Polish Society of Gynaecologists and Obstetricians, and Polish Society of Family Medicine on the diagnosis, therapy, and management of community-acquired lower urinary tract infections.Central European journal of urology · 2024Article
- Chelation in Antibacterial Drugs: From Nitroxoline to Cefiderocol and Beyond.Antibiotics (Basel, Switzerland) · 2022Review
- Antimicrobial activity of clioquinol and nitroxoline: a scoping review.Archives of microbiology · 2022Article
- Compared with Cotrimoxazole Nitroxoline Seems to Be a Better Option for the Treatment and Prophylaxis of Urinary Tract Infections Caused by Multidrug-Resistant Uropathogens: An In Vitro Study.Antibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The number of multi-resistant uropathogens is increasing. A multi-morbid patient developed a symptomatic urinary tract infection with two multi-resistant bacteria, namely Klebsiella pneumoniae and Proteus mirabilis. Nitroxoline was the only drug active against both uropathogens. Obviously, nitroxoline can be an option for the therapy of a urinary tract infection with multi-resistant uropathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.